White Flag Raised: UniQure Gives Up On Glybera, But Not Gene Therapies
UniQure will not seek marketing authorization renewal for Glybera in the EU before it expires in October, but the company does not see the product's commercial failure as a sign that the market won't accept gene therapies or their high price tags.
You may also be interested in...
A bluebird executive spoke during ARM’s Cell and Gene Meeting On The Mesa about why the firm pulled Zynteglo out of the EU, but while progress has been made in the US, long-term challenges remain.
It is not only gene therapy companies that have found European payers hard to convince of the value of their products. Amarin’s proposed European pricing may lead to another US company exit.
US FDA’s Peter Marks says companies are not exchanging information about adenoviral factors, which is probably slowing down the field. He describes NIH's plans for a bespoke gene therapy consortium for vector generation and continued efforts for regulatory harmonization.